Table 2.

Characteristics of the immigrant patients infected with HIV-1 non-B subtypes (N = 29)

Patient code	Origin	Treatment	Subtype in PR gene	Protease inhibitor resistance mutations	Subtype in RT gene	RT inhibitor resistance mutations
SE58	EE	HAART	A	M36I, V77I	N.D.	N.D.
SE115	CSA	Naive	B	M36I	C	None
SE71	CSA	HAART	C	M36I	C	V118I
SE73	EE	Naive	F	L10V, K20R, M36I	F	None
SE43	CSA	HAART	F	M36I	B	None
SE99	EE	Naive	F	K20R, M36I	F	None
SE108	CSA	Naive	F	K20R, M36I	F	None
SE37	SSA	Naive	G	K20I, M36I	G	K70R, A98G
SE103	SSA	Naive	G	K20I, M36I	G	None
SE31	SSA	Naive	J	K20I, M36I, V77I	J	None
SE91	SSA	Naive	K	M36I, L63P	G	E138A
SE11	SSA	HAART	CRF02_AG	K20I, M36I, L63P	G	None
SE16	SSA	TI	CRF02_AG	K20I, M36I	G	None
SE113	N.D.	Naive	CRF02_AG	K20I, M36I	G	None
SE66	WE	HAART	CRF02_AG	K20I, M36I	CRF02_AG	None
SE59	NAF	HAART	CRF02_AG	K20I, M36I, L90M	CRF02_AG	None
SE67	SSA	HAART	CRF02_AG	K20I, M36I, L63P	CRF02_AG	None
SE49	SSA	Naive	CRF02_AG	K20I, M36I, L63P	CRF02_AG	None
SE50	SSA	TI	CRF02_AG	K20I, M36I, L63P, V77I	CRF02_AG	None
SE33	SSA	TI	CRF02_AG	L10V, K20I, M36I	CRF02_AG	None
SE36	CSA	HAART	CRF02_AG	K20I, M36I	CRF02_AG	None
SE101	SSA	Naive	CRF02_AG	K20I, M36I	CRF02_AG	None
SE110	EE	Naive	CRF02_AG	K20I, M36I	CRF02_AG	None
SE111	SSA	HAART	CRF02_AG	K20I, M36I	CRF02_AG	90I
SE34	SSA	TI	CRF02_AG	K20I, M36I	CRF01_AE	L100I
SE96	SSA	Naive	CRF02_AG	K20I, M36I	CRF02_AG	None
SE62	EE	Naive	CRF01_AE	M36I	CRF01_AE	None
SE60	EE	HAART	CRF01_AE	M36I	CRF01_AE	K103N
SE19	SSA	HAART	N.D	N.D.	CRF02_AG	None

Protease and RT inhibitor resistance mutations.

CSA, Central-South America; SSA, Sub-Sahara Africa; EE, Eastern Europe; WE, Western Europe; NAF, Northern Africa. HAART, Highly Active Antiretroviral Therapy. TI, treatment interruption. Bold, major resistance. N.D., not determined.